JNJ

Research snapshot

• Overall rating: 78/100, moderately bullish
• Market-cap class: Mega cap
• Primary view: Johnson & Johnson's diversified medicines, MedTech portfolio, pipeline, and cash generation support durable growth, but patent losses, product litigation, and a full valuation reduce the margin of safety
• Data date: Fiscal quarter ended June 28, 2026; technical data updates after every completed daily candle

The rating combines business quality, fundamentals, growth, valuation, technicals, and risk. It is a research opinion, not a price target or prediction.

1. Company overview

Johnson & Johnson is a global healthcare company focused on Innovative Medicine and MedTech. Following the separation of its consumer-health business, the company is more concentrated in prescription medicines, medical devices, surgical technology, orthopaedics, cardiovascular care, and vision products.

Its two operating segments are:

• Innovative Medicine: Oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and other prescription treatments.
• MedTech: Surgery, orthopaedics, cardiovascular products, electrophysiology, vision care, and related medical technology.

The business model combines patented medicines with procedure-based device revenue. Pharmaceutical products can generate high margins but face clinical, regulatory, and patent risk. MedTech is generally more durable but depends on procedure volumes, hospital budgets, product quality, and surgeon adoption.

2. Fundamentals

Growth and profitability

Second-quarter sales increased 6.6% to $25.31 billion. Operational growth was 5.6%, while adjusted operational growth was 5.7%.

GAAP net earnings were $5.53 billion, or $2.27 per diluted share. Adjusted net earnings increased 5.7% to $7.08 billion, and adjusted EPS increased 4.7% to $2.90. Adjusted results exclude intangible amortization and special items, so the GAAP and adjusted figures should be considered together.

Innovative Medicine sales increased 7.8% to $16.38 billion. Growth from Darzalex, Carvykti, Tecvayli, Rybrevant and Lazcluze, Tremfya, Spravato, and Caplyta more than offset declining Stelara, Remicade, Imbruvica, and Zytiga sales.

MedTech sales increased 4.5% to $8.93 billion. Growth came from surgery, electrophysiology, Shockwave cardiovascular products, contact lenses, and trauma products.

Management raised full-year guidance to approximately $101.1 billion of reported sales and $11.68 of adjusted EPS at the midpoint. Those targets imply reported sales growth of 7.3% and adjusted EPS growth of 8.2%.

Balance sheet and cash flow

• Cash and cash equivalents totaled $20.42 billion.
• Marketable securities were $336 million.
• Short- and long-term debt totaled approximately $49.04 billion.
• Six-month operating cash flow was $11.13 billion.
• Capital expenditures were $2.37 billion.
• Estimated six-month free cash flow was approximately $8.76 billion.
• The company paid $6.36 billion of dividends during the first six months.

Johnson & Johnson has substantial debt but also reliable cash generation and diversified operations. Acquisitions, licensing, litigation payments, dividends, and drug-development spending compete for capital.

Valuation

Near $259 per share, Johnson & Johnson's equity value was approximately $633 billion. The stock traded near 30 times trailing earnings and approximately 22 times the midpoint of 2026 adjusted EPS guidance.

The forward adjusted multiple is reasonable for a high-quality healthcare company but not cheap. Continued pipeline execution and enough growth to replace Stelara are required to support the valuation.

3. Technical analysis

Johnson & Johnson's live panel recalculates its EMA ribbon, 200-day EMA, RSI, MACD, volume, ATR, support, resistance, and trend after each completed daily candle. Pharmaceutical stocks can gap on clinical, regulatory, patent, and legal news, so event risk should be considered before trading.

4. Smart money concepts

The automated panel estimates fair value gaps, order blocks, breaks of structure, changes of character, and liquidity zones. Large trial, earnings, and litigation gaps can remain important reference areas. Confirm zones with price action and volume.

5. Growth drivers and catalysts

• Oncology: Darzalex, Carvykti, Tecvayli, Rybrevant and Lazcluze provide several growth platforms.
• Immunology: Tremfya can offset part of Stelara's decline through new indications and share gains.
• Neuroscience: Spravato and Caplyta expand the company's position in large mental-health markets.
• Pipeline approvals: IMAAVY, new combinations, and label expansions can add indications and extend product life cycles.
• Cardiovascular MedTech: Electrophysiology and Shockwave products address large procedural markets.
• Surgical innovation: Robotics, digital surgery, wound closure, and advanced instruments can improve MedTech growth.
• Raised guidance: Higher 2026 sales and EPS expectations provide a measurable near-term checkpoint.

The main checkpoints are Stelara erosion, oncology growth, pipeline data, MedTech procedure growth, adjusted margin, free cash flow, and legal developments.

6. Risks

• Patent erosion: Stelara and other mature products face biosimilar or generic competition.
• Pipeline risk: Clinical failures, safety findings, or delayed approvals can reduce future revenue.
• Talc litigation: Product-liability claims can create unpredictable legal costs and cash payments.
• Drug pricing: Governments and insurers may reduce prices, limit coverage, or demand larger rebates.
• Product concentration: A smaller group of medicines produces a large share of growth and profit.
• MedTech competition: Abbott, Medtronic, Boston Scientific, Stryker, and others compete for hospital budgets and physician use.
• Product quality: Recalls, manufacturing issues, or device failures can harm patients and create liability.
• Acquisition execution: High-priced acquisitions must deliver clinical and commercial returns.
• Debt and capital allocation: Buybacks, dividends, deals, litigation, and research all require cash.
• Currency and global regulation: International sales expose results to foreign exchange and differing healthcare rules.

7. Scorecard and final view

• Fundamentals: 89/100
• Growth and catalysts: 84/100
• Valuation: 63/100
• Technicals: 82/100
• Risk control: 70/100
• Overall: 78/100

Final view: Johnson & Johnson earns a moderately bullish 78 because its diversified medicines, MedTech portfolio, pipeline, cash flow, and raised guidance support durable growth. Patent erosion, litigation, pricing pressure, debt, and clinical execution prevent a higher rating.

Sources and methodology

• Johnson & Johnson Q2 2026 earnings release filed with the SEC
• Johnson & Johnson Q2 2026 Form 10-Q
• Price snapshot from Finnhub. Valuation estimates use the market price and company-reported financials. The live technical panel recalculates from the latest completed daily market candle.